Dr. Vikrant Sahasrabuddhe received his medical degree from the University of Pune in India, his master's and doctorate degrees in public health from the University of Alabama at Birmingham, and completed fellowship training in epidemiology at the Johns Hopkins University Bloomberg School of Public Health and at the National Cancer Institute. Before joining NCI in 2015, Dr. Sahasrabuddhe was on the faculty at Vanderbilt University for a decade, most recently as Research Associate Professor of Medicine. Dr. Sahasrabuddhe previously served at the NCI in a visiting capacity under an Intergovernmental Personnel Act (IPA) agreement.
Dr. Sahasrabuddhe has conducted both clinic-based and population-based research related to etiology and prevention of infection-associated cervical, anogenital, and hepatobiliary cancers with high or rising incidence and mortality burden. Dr. Sahasrabuddhe's published works and research interests encompass a broad spectrum of clinical and translational research areas related to cancer prevention, including the evaluation of novel and low-cost cervical cancer screening approaches (visual imaging methods and HPV-based biomarkers), optimizing dosing and delivery of HPV vaccination, evaluating the repurposing of commonly-used medications for cancer prevention indications, measuring the effectiveness of scaling-up of cervical cancer prevention implementation programs, and demonstrating synergies in the horizontal integration of vertical public health initiatives.
Dr. Sahasrabuddhe serves as Program Director for the HPV and cervical cancer prevention clinical trials grants portfolio and scientific monitor of HPV and cervical cancer clinical trials within the NCI Division of Cancer Prevention Early Phase Prevention Consortia. He serves as an Adjunct Investigator with the NCI intramural Division of Cancer Epidemiology and Genetics conducting collaborative research related to HPV-based biomarkers and immunologic determinants of HPV-mediated cervical carcinogenesis. He also partners with the NCI Center for Global Health on efforts to promote and support research on HPV-related cancers among HIV-infected populations in low and middle-income countries.